Founding offer · lifetime membership for a single £24, exclusive to our first members · closes 20 June Claim your place →
Global Research Partnerships £24 Lifetime Log inCreate free account

Funded Projects › FP7

NOVO · Novel approaches for prevention and degeneration of pathogenic bacteria biofilms formed on medical devices e.g. catheters

FP7Status: CLOSED1 January 201231 December 2014EU funding €2,971,045

Biofilms are bacterial communities encased in a self-produced hydrated polymeric matrix. An important characteristic of microbial biofilms is their innate resistance to the immune system and susceptibility to antibiotics. This resistance has made microbial biofilms a common cause of medical infections, and difficult-to-treat infections caused by colonized foreign bodies.The NOVO project aims at developing novel approaches to prevent and/or degrade biofilms on catheters elongating their usage in humans up to 10 days.Two complementary approaches for biofilm prophylaxis will be developed:A. Ultrasonic coating of Inorganic antibiofouling agents (process developed by partner BIU) based on a single step sonochemical process to: a) Produce metal fluorides or metal oxides (e.g. MgF2, ZnO) nanoparticles (NPs) and simultaneously b) Impregnate them as antibacterial factors on the catheters. c) Co-coating with bio-inert polymer layers (containing highly hydrophilic antifouling polyethylene glycol, zwitterionic moieties or sugar-groups) grafted onto NPs of adjusted size to the size of MgF2/ZnO NPs or directly onto MgF2/ZnO NPs; to form a hydrogel layer for the protection of the MgF2/ZnO antibiofouling activity.B. Bio/organic antibiofouling activation: 1) Novel coating for catheters based on radical catalyzed polymers to yield anti-bacterial activity. An enzymatic reaction will be applied on the phenolic compounds to generate phenolic radicals to be further polymerized on the catheter surface as an antibiofilm agent. 2) Develop and engineer Cellobiose Dehydrogenases (CDH) that actively oxidizes and degrades biofilms polysaccharides concomitantly producing stoichiometrically H2O2 as antibacterial agent. The enzymes will be coated on the catheters via a lubricant or by the Ultrasonic (US) process after their immobilization. Some novel CDH representatives already show very low activity on glucose which should be removed by further genetic engineering.

Consortium · 12 organisations

coordinator

UNIVERSITAET FUER BODENKULTUR WIEN

AT · €405,402

participant

PRONEFRO - PRODUTOS NEFROLOGICOS SA

PT · €164,240

participant

TECHNISCHE UNIVERSITAET GRAZ

AT · €33,878

participant

MULTIPROFILE HOSPITAL FOR ACTIVE TREATMENT AND EMERGENCY MEDECINE PIROGOV

BG · €123,960

participant

UNIVERSITAET DUISBURG-ESSEN

DE · €276,000

participant

OSM-DAN LTD

IL · €219,410

participant

BAR ILAN UNIVERSITY

IL · €399,740

participant

UNIVERSITAT POLITECNICA DE CATALUNYA

ES · €268,245

participant

ASSOCIACAO UNIVERSIDADE EMPRESA PARA DESENVOLVIMENTO TECMINHO

PT · €280,800

participant

SYNOVO GMBH

DE · €316,800

participant

DEGANIA SILICONE LTD

IL · €182,700

participant

DI DR ANDREAS PAAR KG

AT · €299,870

Research fields

View the official record on CORDIS →

← Find collaborators and more funded projects

Source: CORDIS, Publications Office of the European Union. Global Research Partnerships surfaces open EU research data to help you find collaborators; we are not affiliated with the European Union.